Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
The results from this study confirm the trial experience of high pCR rates after neoadjuvant chemoIO. This supports the use of chemoIO irrespective of KRAS mutation status, PD-L1 expression, and histology, but suggests that this approach may be less suitable for older patients.
Authors
- Federica Pecci (ORCID: https://orcid.org/0009-0000-9289-2007)
- Edoardo Garbo (ORCID: https://orcid.org/0000-0003-2394-9895)
- Adam J. Schoenfeld (ORCID: https://orcid.org/0000-0002-2644-1416)
- Narek Shaverdian (ORCID: https://orcid.org/0000-0002-0294-8749)
- Biagio Ricciuti (ORCID: https://orcid.org/0000-0002-0651-2678)
- Matthew Joseph Bott (ORCID: https://orcid.org/0000-0003-0523-4028)
- Michael Conroy (ORCID: https://orcid.org/0000-0001-9048-5213)
- Alissa J. Cooper (ORCID: https://orcid.org/0000-0001-9124-0082)
- Daniel Richard Gomez (ORCID: https://orcid.org/0009-0003-8617-3868)
- Valsamo Anagnostou (ORCID: https://orcid.org/0000-0001-9480-3047)
- Andrea Arfè (ORCID: https://orcid.org/0000-0003-1534-0609)
- Mihaela D. Aldea (ORCID: https://orcid.org/0000-0001-7685-051X)
- Patrick M. Forde (ORCID: https://orcid.org/0000-0001-6925-6344)
- David R. Jones (ORCID: https://orcid.org/0000-0002-3318-0146)
- Teresa Gorría
- Mark M. Awad (ORCID: https://orcid.org/0000-0003-0928-5244)
- Jamie E. Chaft (ORCID: https://orcid.org/0000-0002-5838-9982)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- Trinity College (CA)
- Trinity College Dublin (IE)
- Cornell University (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1002/cncr.70081
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Memorial Sloan-Kettering Cancer Center
- European School of Oncology
- National Cancer Institute